Skip to main content
. 2024 Nov 26;13(23):7181. doi: 10.3390/jcm13237181

Table 1.

CWA-APTT and CWA-sTF/FIXa in HVs and patients with CLD, cancer, ACI, and AMI.

Second Derivative First Derivative Fibrin Formation
APTT Peak Time Peak Height Peak Time Peak Width Peak Height Peak Time Peak Height
HVs 36.8
(35.6–38.9)
731
(600–804)
34.7
(33.7–36.6)
36.0
(31.1–42.0)
231
(201–273)
36.8
(35.6–38.9)
196
(171–214)
CLD 35.8
(33.1–38.4)
888 ***
(752–1033)
33.8
(31.4–36.5)
35.0
(31.5–42.1)
292 ***
(246–339)
35.8
(33.1–38.4)
220 ***
(198–250)
Cancer 36.8
(34.1–38.2)
955 ***
(824–1168)
34.3
(31.8–36.1)
41.1 ***
(34.9–46.5)
315 ***
(268–394)
36.8
(34.1–38.2)
253 ***
(217–308)
ACI 35.8
(33.3–38.1)
997 ***
(853–1191)
33.7
(31.4–36.1)
37.7
(33.0–42.8)
327 ***
(276–404)
35.8
(33.3–38.1)
239 ***
(211–282)
AMI 39.2 **
(35.4–44.8)
1069 ***
(865–1374)
37.6 **
(33.6–42.0)
42.5 ***
(37.4–50.5)
400 ***
(324–495)
39.2 **
(35.4–44.8)
324 ***
(273–395)
sTF/FIXa Peak time Peak height Peak time Peak width Peak height Peak time Peak height
HVs 71.3
(65.1–79.2)
31.9
(28.7–40.0)
91.3
(85.8–98.0)
145
(134–158)
65.0
(55.4–71.9)
92.2
(86.9–97.8)
315
(255–373)
CLD 68.2 *
(61.5–64.7)
44.5 ***
(36.6–56.9)
84.5 ***
(78.8–90.4)
138 ***
(126–145)
83.6 ***
(71.3–101)
85.7 ***
(79.7–91.3)
330
(277–380)
Cancer 70.5
(62.7–79.3)
43.1 ***
(31.3–62.1)
90.1
(79.8–100)
152
(131–170)
88.3 ***
(73.2–114)
92.4
(81.7–102)
344 *
(284–432)
ACI 63.8 **
(54.3–74.0)
47.0 ***
(36.2–60.1)
85.3 **
(77.0–94.4)
142
(132–154)
91.1 ***
(75.6–118)
85.8 ***
(78.2–94.6)
347 **
(302–413)
AMI 68.1 (56.6–77.4) 46.8 ***
(33.0–60.2)
93.0
(84.0–107)
162 ***
(142–183)
112 ***
(81.1–138)
94.6
(84.5–108)
473 ***
(393–550)

CWA, clot waveform analysis; APTT, activated partial thromboplastin time; sTF/FIXa, small amount of tissue factor activation assay; HVs, healthy volunteers; CLD, chronic liver disease, ACI, acute cerebral infarction; AMI, acute myocardial infarction; *, p < 0.05; **, p < 0.01; ***, p < 0.001 in comparison to HVs.